Cel Sci Corporation (CVM)

[lightrock]

Nobody said anything yet, but I put some +1 on your post :)

I am not aware of anything else that could possibly fit this description:

Immunotherapies are already revolutionising treatment for quite a few cancer types, similarly it also helps to cure a patient with Head and neck cancer. Immune system dysfunction plays a role in both the expansion and progression of head and neck squamous cell carcinoma, emphasising the potential role for immunotherapy to improve outcomes in this disease.

Immunotherapy has been an effective treatment for patients with certain types of cancer that have been resistant to chemotherapy and radiation treatment. Immunotherapy can “train” the immune system to remember cancer cells. This “immunomemory” may result in longer-lasting remissions.

Even as per a new study, the estimated survival rate after 12 months for those that just received chemotherapy was 49.4 percent — in other words, just under half of those patients survived for a year. But the survival rate for patients who went for immunotherapy was dramatically higher: 69.2 percent. The result is yet another notch in the belt of immunotherapies that are quickly moving from research labs into clinics, with exciting results for many cancers.

If that is in reference to us, then the last time the IDMC met they
should have raised a flag. I am afraid we are rigorously sticking to
protocol when it is already not physically possible to fail.